FindTrial
Sign In

Studies on the effect of hyperglycemia on the structure of the fibrin-gel and on the glycosylation of fibrin , and in what way the use of acetylsalicylic acid may interfere with this effect. - Effect of ASA on the fibrin-gel.

Studies on the effect of hyperglycemia on the structure of the fibrin-gel and on the glycosylation of fibrin , and in what way the use of acetylsalicylic acid may interfere with this effect. - Effect of ASA on the fibrin-gel.

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2005-005723-34-SE
Enrollment
Unknown
Registered
2005-12-22
Start date
2006-03-23
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with type 1 diabetes, not on ASA for the last 6 months, without a history of bleeding disorder and with a normal trobocyte count.

Interventions

Trade Name: Trombyl (acetylsalicylic acid) Product Name: Trombyl Product Code: Trombyl Pharmaceutical Form: Tablet INN or Proposed INN: acetylsalcylic acid Concentration unit: mg milligram(s) Concentr

Sponsors

Dept of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients with type 1 diabetes with a HbA1c =65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: see above

Design outcomes

Primary

MeasureTime frame
Main Objective: To find out of ASA may interfere with the effect of hyperglycemia on the porosity of the fibrtin-gel (in vitro).;Secondary Objective: To find out if there is an interaction between glucose and ASA on the glycosylation/ acetylation of fibrinogen, and further if the magniotude of "chronic" hyperglycemia (as evaluated by the HbA1c level) or the dose of ASA ( 75 or 300 mg) is of importance.;Primary end point(s): Fibrin gel porosity—

Countries

Sweden

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026